By Destiny Obinna
The World Health Organisation (WHO) has raised the alarm over the growing threat of antimicrobial resistance (AMR), warning that millions of patients remain vulnerable to drug-resistant infections despite increasing efforts by countries to tackle the problem.
The global health agency said inadequate diagnostic facilities, poor access to appropriate treatment and insufficient funding for national action plans were undermining the fight against antimicrobial resistance.
According to new findings released on Monday, 173 countries have developed national plans to address AMR, more than doubling the 79 countries recorded in 2017.
However, WHO expressed concern that only 22 per cent of countries have secured the necessary funding and achieved full implementation of their national action plans.
The report further disclosed that approximately one in six laboratory-confirmed bacterial infections worldwide in 2023 was resistant to antibiotics, highlighting the growing threat to public health.
Antimicrobial resistance occurs when bacteria and other microorganisms develop the ability to withstand medicines designed to kill them or stop their growth, making infections increasingly difficult to treat.
The development also threatens routine medical procedures, including surgery, childbirth and cancer treatment, where effective antibiotics are often essential.
Reacting to the findings, WHO Director-General, Dr Tedros Adhanom Ghebreyesus, said the growing number of countries with national AMR plans was encouraging but warned that having policies without implementing them would not protect patients.
“National plans are essential for protecting the medicines that protect us, and the fact that most countries now have plans in place is great news,” Tedros said.
“But an unfulfilled plan helps no one. We call on all countries to implement their plans with investments in infection prevention, surveillance, equitable access to essential antimicrobials and quality diagnostics,” he added.
The findings are contained in the 2026 Tracking Antimicrobial Resistance Country Self-assessment Survey (TrACSS), completed by 183 countries, representing 94 per cent of WHO Member States.
A major concern highlighted in the assessment is the poor availability of diagnostic facilities capable of identifying drug-resistant infections.
WHO disclosed that only 36 per cent of countries have national reference laboratories equipped to test selected bacteria and fungi, falling short of the global target of 80 per cent by 2030.
The agency warned that inadequate testing exposes patients to the risk of receiving ineffective or unnecessary antibiotics, while resistant infections and outbreaks could remain undetected.
The report also showed that only 63 per cent of countries have guidelines on the appropriate use of antimicrobial medicines, while just over half have surveillance systems to monitor antibiotic consumption and track resistance levels.
To address the gaps, WHO has introduced two practical tools under its AMR Diagnostic Initiative to help countries strengthen laboratory capacity.
The tools provide a prioritised catalogue of diagnostic tests and step-by-step guidance to assist clinical laboratories in identifying bacterial and fungal infections.
WHO said improved diagnostic capacity would help health professionals identify infections accurately and ensure patients receive appropriate medicines.
The agency has also called for coordinated action across human, animal, plant and environmental health sectors to prevent the emergence and spread of resistant microorganisms.
The call comes ahead of World Antimicrobial Resistance Awareness Week, scheduled for November 18 to 24, with the 2026 theme, “One Health, One Action: Prevent AMR Now”.
The campaign seeks to mobilise governments, health professionals, farmers, veterinarians, environmental experts and communities to strengthen efforts against antimicrobial resistance.
WHO warned that without sustained investment in prevention, surveillance, laboratory testing and appropriate treatment, the growing threat of drug-resistant infections could further undermine global health systems.
